

Special Issue

Hepatitis B Virus: Its Life Cycle and the Therapeutic Targets

Message from the Guest Editor

We do not have many or good options to the save lives of HBV-infected people around the world. Finding NTCP (sodium taurocholate co-transporting peptide) has enabled us to analyze the HBV life cycle in vitro using human hepatoma cell lines, though it may not be enough. Much knowledge of the HBV life cycle has been accumulating, and thus it is time to think of the next generation of HBV therapy. This Special Issue will accept all kinds of manuscripts (reviews, research articles, and short communications). Based on the HBV life cycle, what kind of therapy will be designed? What factors could be targets for HBV treatment? Conceptual ideas on HBV treatment and analyses on new compounds to act on cellular targets are also of interest. We would like to discuss the future of HBV treatment, with a view to conquering the infection.

Guest Editor

Prof. Dr. Keiji Ueda

Division of Virology, Department of Microbiology and Immunology, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan

Deadline for manuscript submissions

closed (31 December 2021)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/67619

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.2 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).